Artificial intelligence

Showing 9 of 0 results

• ISPOR 2026 reflections: AI, access, and the evolving role of RWE in oncology
  • Real-world evidence
  • Event recap
  • HTA and market access
  • Artificial intelligence
• From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Artificial intelligence
• Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Machine learning
  • Metastatic breast cancer
  • Artificial intelligence
• Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Non-small cell lung cancer
  • Artificial intelligence
• External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1–high metastatic non–small cell lung cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Precision medicine
  • Machine learning
  • Non-small cell lung cancer
  • Artificial intelligence
• Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Breast cancer
  • Artificial intelligence
• Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Comparative effectiveness
  • Head and neck cancer
  • Artificial intelligence
• Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Comparative effectiveness
  • Non-small cell lung cancer
  • Artificial intelligence
• Unlocking the next level of RWD: Flatiron’s Scientific Vision
  • Real-world evidence
  • Data science
  • Machine learning
  • Artificial intelligence